Immunomodulators: myths and reality

Abstract

Medicines and substances intended for selective action on various parts of the immune system in order to prevent and treat infectious and some non-infectious diseases are considered. Special attention is placed to up-to-date requirements of evidence-based medicine. Examples of creation, development, production and implementation of modern immunotropic medicines are given. Promising strategies of applying technologies for creating and using immunotropic drugs that activate innate and adaptive immunity in medical practice are discussed.

Keywords:immunopharmacology; immunomodulators; immunostimulators; immunocyte activators; glycopeptide, innate immunity; adaptive immunity

For citation: Khaitov R.M. Immunomodulators: myths and reality. Immunologiya. 2020; 41 (2): 101-6. DOI: 10.33029/ 0206-4952-2020-41-2-101-106 (in Russian)

Funding. The study had no sponsor support.

Conflict of interests. The author declares no conflict of interests.

References

1. Petrov R.V., Khaitov R.M. Artificial antigens and vaccines. Moscow: Meditsina, 1988: 288 p. (in Russian)

2. Khaitov R.M. Results and prospects of research on the creation of artificial vaccines. Immunologiya. 1985; 5: 7–11. (in Russian)

3. Petrov R.V., Khaitov R.M., Kabanov V.A. Artificial antigens and vaccines based on non natural polyelectrolytes. Sov. Sci. Rev. J. Physicochem. Biol. 1984; 5: 277–322.

4. Petrov R.V., Khaitov R.M., Zhdanov V.M. Influenza virus antigens conjugated vita a synthetic polyelectrolyte: a novel model of vaccines. Vaccine. 1985; 3: 392–400.

5. Petrov R.V., Khaitov R.M., Semenov B.F. Artificial vaccines against salmonella infection. New approaches to vaccine development. In: Proc. Meeting. Geneva : WHO, 1983; Bell R., Torrigiany G. (eds). Basel, 1984: 390–402.

6. Khaitov R.M. Vaccines based on synthetic polyions and peptides. Ann. N. Y. Acad. Sci. 1993; 685: 788–802.

7. Khaitov R.M. Molecular bases for the construction of artificial immunogens and vaccines based on synthetic polyions. Allergy Proc. 1985; 16: 255–60.

8. Petrov R.V., Khaitov R.M. New national trivalent conjugated polymer-subunit vaccine «Grippol». Vaktsinatsiya. 1999; 5: 6–7. (in Russian)

9. Petrov R.V., Khaitov R.M. Immunogens and vaccines of new generation. Moscow: GEOTAR-Media, 2011: 606 p. (in Russian)

10. Khaitov R.M., Ataullakhanov R.I., Shulzhenko A.E. Immunotherapy. A guide for physicians. 2nd ed. Moscow: GEOTAR-Media, 2018: 786 p. (in Russian)

11. Khaitov R.M. Immunology. 3rd ed. Moscow: GEOTAR-Media, 2018: 496 p. (in Russian)

12. Ivanov V.T., Khaitov R.M., Andronova T.M., Pinegin B.V. Lycopid (glucosaminylmuramyldipeptide) – a new Russian highly effective immunomodulator for the treatment and prevention of diseases associated with secondary immunological insufficiency. Immunologiya. 1996; 2: 4–6. (in Russian)

13. Pinegin B.V., Andronova T.M. Some theoretical and practical issues of clinical application of immunomodulator Likopid. Immunologiya, 1998; 18: 60–3. (in Russian)

14. Bogdanov I.G., Dalev P.G., Gurvich A.I., et al. Antitumour glycopeptides from Lactobacillus bulgaricus. FEBS Lett. 1975; 57: 259–61.

15. Bogdanov I.G., Velichkov V.T., Gurvich A.L. Antitumor action of glycopeotide from the cell wall of Lactobacillus bulgaricus. Exp. Biol. Med. 1978; 84: 1750–3.

16. Andronova T.M., Rostovtseva L.I., Dobrushkina E.P. On the structure of antitumor glycopeptide from the cell wall of Lactobacillus bulgaricus. Bioorganicheskaya khimiya. 1980; 6 (12): 1830–40. (in Russian)

17. Rostovtseva L.I., Andronova T.M., Malkova V.P. Synthesis and antitumor action of glycopeptides containing N-acetylglucosaminyl-(beta1-4)-N-acetylmuramyl-disaccharide link. Bioorganicheskaya khimiya.1981; 7 (12): 1843–58. (in Russian)

18. Andronova T.M., Ivanov V.T. The structure and immunomodulating function of glucosaminylmuramil peptides. Sov. Med. Rev. D. Immunol. 1991; 4: 1–63.

19. Khaitov R.M., Kulakov A.V., Pinegin B.V., Makarov E.A., et al. The study of serum level and immunochemical properties of natural antibodies to N-acetylglucosaminyl-N-acetylmuramil dipeptide in healthy donors. Russ. J. Immunol. 1996; 1 (1): 5–8.

20. Bomford R., Stapleton M., Windsor S., McKnight A., et al. The control of the antibody isotope response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res. Hum. Retroviruses. 1992; 8 (10): 1765–71.

21. Pinegin B.V., Kulakov A.V., Yarilin D.A., Khaitov R.M., et al. Competitive analysis of specificity of natural antibodies against the epitope of bacterial cell wall peptidoglican: glucosaminylmuramyl dipeptide carrying adjuvant activity. Immunol. Infect. Dis. 1996; 6 (3–4): 133–7.

22. Williamson D., Chawla M., Marks R. GMDP for psoriasis. Lancet. 1998; 352: 545.

23. Armstrong N.A., Bolton E.J., Morris D.L. Study of the reduction of chemotherapy induced neutropenia in mice using glucosaminylmuramil dipeptide. Arzneimittelforshung. 1999; 49 (8): 716–20.

24. Khaitov R.M. The main target of immunological actions of GMDP (Likopid). Immunologiya, 1994; 2: 47–50. (in Russian)

25. Pinegin B.V., Khaitov R.M. Modern principles of immunotropic drugs creation. Immunologiya. 2019; 40 (6): 57–62. (in Russian)

26. Khavinson V.Kh., Malinin V.V. Gerontological Aspects of Genomic Peptide Regulation. Basel, Switzerland: Karger AG, 2005: 104 p.

27. Khaitov R.M., Garib F.Yu. Immunology. Atlas. 2nd ed. Moscow: GEOTAR-Media, 2020: 416 p. (in Russian)

28. Dontsov V.I., Podkolzin A.A. Galavit – a new immunomodulator with a bioactivating and regenerating effect. Ezhegodnik natsional’nogo gerontologicheskogo tsentra. 2001; 4: 70–80. (in Russian)

29. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 1974; 59 (4): 1317–25.

30. Chedid L., Audibert F., Johnson A.G. Biological activities of muramyl dipeptide, a synthetic glycopeptides analogous to bacterial immunoregulating agents. Prog. Allergy. 1978; 25: 63–105.

31. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., et al. NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 2003; 278 (11): 8869–72.

32. Inohara N., Ogura Y., Fontalba A., Gutierrez O., et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn’s disease. J. Biol. Chem.2003; 278 (8): 5509–12.

33. Meshcheryakova E., Makarov E., Andronova T., Ivanov V., et al. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminyl-N-acetylmuramyl peptides. Vaccine. 2007; 25 (23): 4515–20.

34. Strobe W., Murray P., Kitani A., et al. Signaling pathways and molecular interactions of NOD1 and NOD2. Nat. Rev. Immunol. 2006; 6: 9–20.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»